Tandem Diabetes Care has announced that it expects to treble its worldwide customer base to one million people within the next five years, mainly by
In a report written for JDRF by Brian Herrick, Tandem Diabetes has gained FDA clearance of an expanded paediatric indication for the Tandem t:slim X2
Tandem Diabetes Care has launched the t:slim X2 insulin pump with Control-IQ technology, an advanced hybrid-closed loop feature designed to help increase time in range. It is the first and
In August 2018 in the US Tandem Diabetes Care launched its insulin pump with predictive low glucose suspend feature. Tandem gained FDA approval for the
The U.S. Food and Drug Administration (FDA) has approved the t:slim X2 insulin pump with Basal-IQ technology from Tandem Diabetes Care. Basal-IQ is a predictive
This insulin pump from an American manufacturer is set to create a stir in Britain, bringing slim, simple and sophisticated options to the choice currently
Tandem Diabetes Care, the medical device company and manufacturer of the only touchscreen insulin pumps available in the US has entered into a distribution agreement
